Indian high court backs Bristol-Myers' Sprycel patent; Pfizer presses judge to disqualify Zoloft expert witness;

@FiercePharma: Horizon targets Depomed's pain portfolio with $3B hostile bid. News | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Report | Follow @CarlyHFierce

> India's high court upheld Bristol-Myers Squibb's ($BMY) patent on the cancer drug Sprycel (dasatanib); domestic drugmaker BDR Pharmaceuticals had challenged the patent and asked government officials for a compulsory license on the drug. Report

> Pfizer ($PFE) is once again asking a federal judge to disqualify a key expert witness in litigation over the antidepressant Zoloft and its potential link to birth defects. Report

> Ranbaxy Laboratories' India operations chief resigned in the wake of its sale to Sun Pharma; Rajeev Sibal is expected to join rival drugmaker Lupin, according to media reports. Story

> Teva Pharmaceutical ($TEVA) launched its extended-regimen birth control pill Seasonique in several European markets. Report

> Drug distributor Cardinal Health ($CAH) wrapped up its $1.1 billion buyout of Harvard Drug Group, a supplier of generic drugs, over-the-counter meds and related products. Report

Medical Device News

@FierceMedDev: Natera bags $180M in IPO to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: FDA warns that Maquet's anesthesia system could lead to a fatal stop in ventilation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: BG Medicine gets FDA blessing for automated chronic heart failure test. Article | Follow @EmilyWFierce

> DEKA gets $7M from DARPA to develop prosthetic arm with a sense of touch. News

> Report: Repeal of medical device tax gaining traction in Congress. More

Biotech News

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Aimmune joins the biotech IPO scrum in search of $115M--plus a roundup of biotech IPO news. More | Follow @JohnCFierce

@DamianFierce: $AGN is paying $MRK $250M to become the roughly 127th company developing CGRP blockers for migraine. Release | Follow @DamianFierce

> Esperion's PCSK9 spoiler clears another FDA roadblock as it heads to Phase III. Story

> Essex Woodlands raises $360M for new life sciences fund. Item

> Aimmune joins the biotech IPO scrum in search of $115M. Article

Drug Delivery News

> Natural bioluminescence provides inside look at drug-cell interactions. Story

> FDA to review modified-release version of Pfizer's Xeljanz for rheumatoid arthritis. More

> Novo ends microneedle patch diabetes partnership with Zosano. Article

> UCSB team tackles aggressive kidney disease by hitching a ride into cysts. Story

> China's Wuzhou says it will take 10% stake in oral insulin specialist Oramed for $52M. Report

Pharma Manufacturing News

> India's Lupin gets Russian production site in deal for Biocom. More

> Boehringer Ingelheim unloads vet plant in Iowa to contract manufacturer. Story

> FDA warns consumers to check any generic Valium bought online; it may be dangerous. Article

> Actavis yanks more than half a million boxes of birth control pills for packaging faux pas. News

> Europe says Israel and Brazil can ship APIs without having to certify them. Item

Pharma Asia News

> China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus. More

> Shanghai, Shenzhen IPO halts won't spoil the China healthcare party. Story

> More trouble for India's CROs as Quest Life Sciences hauled up by WHO in HIV trial. Report

> Indian court upholds BMS Sprycel patent, but list of challengers grows. News

> Alibaba Health plans wider online sales push in China as competition heats up. Article

And Finally... Breast cancer screenings may not lead to fewer deaths but may lead to overdiagnosis, researchers said. Report